Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Genfit SA (ADR) (OQ:GNFT)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for GNFT*US within the last 6 months
Loading...
See all filings within the past 6 months

Valuation Ratios

Industry
Sector
Beta
1.08
--
--
Price to Sales - TTM
4.25
4.32
3.29
Price to Book - most recent quarter
2.40
2.11
2.16
Price to Cash Flow per share - TTM
--
11.71
13.58
Price to Free Cash Flow per share - TTM
--
23.01
23.27
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

See business summary

 

Twitter

Search (past week) for $GNFT

  • No tweets found